FDA Law Blog: Biosimilars

OCTOBER 13, 2024

Tobolowsky — The Rare Pediatric Disease Priority Review Voucher program has had a bit of a tumultuous history in its 12 short years of existence. Over 50 rare pediatric disease priority review vouchers have been awarded to date. We heard and felt the anxiety from many of our clients about the uncertainty this caused.

Disease 64

Disease FDA FDA Approval Government 64

Broad Institute

MAY 9, 2024

Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery.

Clinical Trials 52

Clinical Trials Clinical Development Disease Science 52

The Pharma Data

MARCH 31, 2022

. €650 million fixed rate notes, due April 2029, bearing interest at an annual rate of 1.250%. million patients, provided with essential medicines by the global health unit, for the treatment of non-communicable diseases in 40 of the world’s poorest countries, between 2022 and 2026.

Treatment 52

Treatment Government Vaccine Disease 52

The Pharma Data

OCTOBER 9, 2021

“While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases. About LATTICE-UC. About Ulcerative Colitis.

Disease 52

Disease Trials Science Immune Response 52

The Pharma Data

FEBRUARY 22, 2022

Amgen (NASDAQ:AMGN) today announced the issuance of its inaugural $750 million green bond, with a 3.000% semi-annual coupon and maturing in 2029, to advance the environmental goals that are part of Amgen’s environmental, social and governance (ESG) framework.

Government 52

Government International Production Science 52

Vial

MARCH 1, 2024

billion by 2029. It ensures regulatory compliance for over 15 long-term post-authorization safety studies across eight disease indications. The Vial CRO Small CROs like Vial offer a high degree of specialization in specific disease areas and geographic focus. from 2024 to reach US$129.8

Clinical Trials 52

Clinical Trials Clinical Research Trials Laboratories 52

The Pharma Data

JANUARY 25, 2021

Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of $650 million aggregate principal amount of 2.25% convertible senior notes due 2029 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Marketing 52

Marketing Disease Clinical Trials Clinical Development 52